Dr. Charles S. Fuchs M.D. serves as Independent Director of the Company. Dr. Fuchs is an internationally recognized expert in gastrointestinal cancers, cancer epidemiology and cancer drug development, and conducts research assessing novel therapeutic approaches in oncology. Dr. Fuchs is the Richard Sackler and Jonathan Sackler Professor of Medicine, Director of the Yale Cancer Center and Physician-in-Chief of the Smilow Cancer Hospital since January 2017. He was previously professor of medicine at Harvard Medical School and chief of the gastrointestinal oncology division and the Robert T. and Judith B. Hale Chair in Pancreatic Cancer at Dana-Farber Cancer Institute from July 2007 to December 2017. Dr. Fuchs received his medical degree from Harvard Medical School in 1986. He completed his medical residency at Brigham and Women’s Hospital, where he also served as chief medical resident, and completed his medical oncology fellowship at Dana-Farber Cancer Institute. In 1994, he received his M.P.H. from Harvard School of Public Health.
As the Independent Director of CytomX Therapeutics Inc, the total compensation of Charles Fuchs at CytomX Therapeutics Inc is $127,122. There are 13 executives at CytomX Therapeutics Inc getting paid more, with Sean McCarthy having the highest compensation of $3,769,930.
Charles Fuchs is 59, he's been the Independent Director of CytomX Therapeutics Inc since 2017. There are 8 older and 9 younger executives at CytomX Therapeutics Inc. The oldest executive at CytomX Therapeutics Inc is Frederick W. Gluck, 86, who is the Co-Founder & Independent Director.
Charles's mailing address filed with the SEC is C/O CYTOMX THERAPEUTICS, INC., 151 OYSTER POINT BLVD., STE. 400, SOUTH SAN FRANCISCO, CA, 94080.
Over the last 10 years, insiders at CytomX Therapeutics Inc have traded over $57,157,858 worth of CytomX Therapeutics Inc stock and bought 662,000 units worth $7,876,720 . The most active insiders traders include Partners L P/Ilbiotechnolog..., Harbor Master Investors (Ca..., and James E Deerfield Mgmt L.P..... On average, CytomX Therapeutics Inc executives and independent directors trade stock every 20 days with the average trade being worth of $48,707. The most recent stock trade was executed by Jeffrey B Landau on 20 August 2024, trading 11,250 units of CTMX stock currently worth $14,738.
cytomx is an oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on its probody technology platform. the company uses the platform to create development-stage proprietary cancer immunotherapies against clinically-validated targets, as well as to develop first-in-class investigational cancer therapeutics against novel targets. cytomx believes that its probody platform has the potential to improve the combined efficacy and safety profile of monoclonal antibody modalities, including cancer immunotherapies, antibody drug conjugates and t-cell-recruiting bispecific antibodies. probody therapeutics are designed to take advantage of unique conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues. investigational probody therapeutics are being developed that address clinically-validated cancer targets in immuno-oncology, such as pd-l1 against which o
CytomX Therapeutics Inc executives and other stock owners filed with the SEC include: